TLRY Quote, Financials, Valuation and Earnings

Edesa Biotech, Inc. has a net margin of -20% compared to Tilray Brands, Inc.'s net margin of --. Tilray Brands, Inc.'s return on equity of -98.18% beat Edesa Biotech, Inc.'s return on equity of -77.48%.

Tilray Brands, Inc. has a consensus price target of $11.83, signalling upside risk potential of 55.18%. On the other hand Edesa Biotech, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 928.04%. Given that Edesa Biotech, Inc. has higher upside potential than Tilray Brands, Inc., analysts believe Edesa Biotech, Inc. is more attractive than Tilray Brands, Inc..

Tilray Brands, Inc. has a beta of 2.022, which suggesting that the stock is 102.181% more volatile than S&P 500. In comparison Edesa Biotech, Inc. has a beta of 0.208, suggesting its less volatile than the S&P 500 by 79.169%.

Tilray Brands, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edesa Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tilray Brands, Inc. pays -- of its earnings as a dividend. Edesa Biotech, Inc. pays out -- of its earnings as a dividend.

Tilray Brands, Inc. quarterly revenues are $217.5M, which are larger than Edesa Biotech, Inc. quarterly revenues of --. Tilray Brands, Inc.'s net income of -$43.5M is lower than Edesa Biotech, Inc.'s net income of -$2.2M. Notably, Tilray Brands, Inc.'s price-to-earnings ratio is -- while Edesa Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tilray Brands, Inc. is 0.92x versus 31.22x for Edesa Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Lexaria Bioscience Corp. has a net margin of -20% compared to Tilray Brands, Inc.'s net margin of -2178.51%. Tilray Brands, Inc.'s return on equity of -98.18% beat Lexaria Bioscience Corp.'s return on equity of -189.86%.

Tilray Brands, Inc. has a consensus price target of $11.83, signalling upside risk potential of 55.18%. On the other hand Lexaria Bioscience Corp. has an analysts' consensus of $4.50 which suggests that it could grow by 605.77%. Given that Lexaria Bioscience Corp. has higher upside potential than Tilray Brands, Inc., analysts believe Lexaria Bioscience Corp. is more attractive than Tilray Brands, Inc..

Tilray Brands, Inc. has a beta of 2.022, which suggesting that the stock is 102.181% more volatile than S&P 500. In comparison Lexaria Bioscience Corp. has a beta of 0.562, suggesting its less volatile than the S&P 500 by 43.753%.

Tilray Brands, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lexaria Bioscience Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tilray Brands, Inc. pays -- of its earnings as a dividend. Lexaria Bioscience Corp. pays out -- of its earnings as a dividend.

Tilray Brands, Inc. quarterly revenues are $217.5M, which are larger than Lexaria Bioscience Corp. quarterly revenues of --. Tilray Brands, Inc.'s net income of -$43.5M is lower than Lexaria Bioscience Corp.'s net income of -$1.6M. Notably, Tilray Brands, Inc.'s price-to-earnings ratio is -- while Lexaria Bioscience Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tilray Brands, Inc. is 0.92x versus 23.44x for Lexaria Bioscience Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Oncolytics Biotech, Inc. has a net margin of -20% compared to Tilray Brands, Inc.'s net margin of --. Tilray Brands, Inc.'s return on equity of -98.18% beat Oncolytics Biotech, Inc.'s return on equity of -635.07%.

Tilray Brands, Inc. has a consensus price target of $11.83, signalling upside risk potential of 55.18%. On the other hand Oncolytics Biotech, Inc. has an analysts' consensus of $10.30 which suggests that it could grow by 1107.32%. Given that Oncolytics Biotech, Inc. has higher upside potential than Tilray Brands, Inc., analysts believe Oncolytics Biotech, Inc. is more attractive than Tilray Brands, Inc..

Tilray Brands, Inc. has a beta of 2.022, which suggesting that the stock is 102.181% more volatile than S&P 500. In comparison Oncolytics Biotech, Inc. has a beta of 0.988, suggesting its less volatile than the S&P 500 by 1.202%.

Tilray Brands, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oncolytics Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tilray Brands, Inc. pays -- of its earnings as a dividend. Oncolytics Biotech, Inc. pays out -- of its earnings as a dividend.

Tilray Brands, Inc. quarterly revenues are $217.5M, which are larger than Oncolytics Biotech, Inc. quarterly revenues of --. Tilray Brands, Inc.'s net income of -$43.5M is lower than Oncolytics Biotech, Inc.'s net income of -$10.5M. Notably, Tilray Brands, Inc.'s price-to-earnings ratio is -- while Oncolytics Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tilray Brands, Inc. is 0.92x versus -- for Oncolytics Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Xenon Pharmaceuticals, Inc. has a net margin of -20% compared to Tilray Brands, Inc.'s net margin of -867.29%. Tilray Brands, Inc.'s return on equity of -98.18% beat Xenon Pharmaceuticals, Inc.'s return on equity of -44.39%.

Tilray Brands, Inc. has a consensus price target of $11.83, signalling upside risk potential of 55.18%. On the other hand Xenon Pharmaceuticals, Inc. has an analysts' consensus of $55.82 which suggests that it could grow by 30.55%. Given that Tilray Brands, Inc. has higher upside potential than Xenon Pharmaceuticals, Inc., analysts believe Tilray Brands, Inc. is more attractive than Xenon Pharmaceuticals, Inc..

Tilray Brands, Inc. has a beta of 2.022, which suggesting that the stock is 102.181% more volatile than S&P 500. In comparison Xenon Pharmaceuticals, Inc. has a beta of 0.957, suggesting its less volatile than the S&P 500 by 4.276%.

Tilray Brands, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xenon Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tilray Brands, Inc. pays -- of its earnings as a dividend. Xenon Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Tilray Brands, Inc. quarterly revenues are $217.5M, which are larger than Xenon Pharmaceuticals, Inc. quarterly revenues of --. Tilray Brands, Inc.'s net income of -$43.5M is higher than Xenon Pharmaceuticals, Inc.'s net income of -$90.9M. Notably, Tilray Brands, Inc.'s price-to-earnings ratio is -- while Xenon Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tilray Brands, Inc. is 0.92x versus 449.37x for Xenon Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.